DBV Technologies (NASDAQ:DBVT) Stock Rating Upgraded by Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Friday.

Other research analysts have also issued research reports about the company. Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target (up from $16.00) on shares of DBV Technologies in a research note on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $16.08.

DBV Technologies Stock Up 8.5%

DBVT opened at $14.00 on Friday. The firm has a market cap of $503.52 million, a P/E ratio of -2.71 and a beta of -0.49. The business’s fifty day simple moving average is $13.66 and its 200 day simple moving average is $11.01. DBV Technologies has a 52 week low of $2.74 and a 52 week high of $18.00.

Institutional Investors Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund purchased a new stake in shares of DBV Technologies during the third quarter worth about $34,000. Two Sigma Investments LP acquired a new stake in DBV Technologies during the 3rd quarter valued at approximately $167,000. Citadel Advisors LLC purchased a new stake in DBV Technologies during the 3rd quarter worth approximately $220,000. DLD Asset Management LP acquired a new position in shares of DBV Technologies in the 3rd quarter valued at approximately $250,000. Finally, Nan Fung Trinity HK Ltd. acquired a new position in shares of DBV Technologies in the 2nd quarter valued at approximately $340,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.